 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TARRYTOWN, NY / ACCESSWIRE / November 22, 2023 / PaxMedica, Inc. (NASDAQ:PXMD) ('PaxMedica' or the 'Company'), a biopharmaceutical company focused on advancing treatments for neurological disorders...

PaxMedica Announces Closing of $7.0 Million Public Offering

InvestorPlace - Stock Market News, Stock Advice & Trading Tips
PXMD stock is sinking lower after the company announced a $7 million public offering of over 5 million shares and warrants.
The post Why...

Why Is PaxMedica (PXMD) Stock Down 40% Today?

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining over 100 points on Monday.
The Dow traded up 0.34% to 35,064.42 while the NASDAQ rose 0.80% to 14,238.67. The S&P...

Crude Oil Gains Over 2%; PaxMedica Shares Plunge

TARRYTOWN, NY / ACCESSWIRE / November 20, 2023 / PaxMedica, Inc. (NASDAQ:PXMD) ('PaxMedica' or the 'Company'), a biopharmaceutical company focused on advancing treatments for neurological disorders...

PaxMedica Announces Pricing of $7.0 Million Public Offering

LOS ANGELES, Nov. 17, 2023 (GLOBE NEWSWIRE) -- via IBN PaxMedica, Inc. (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announces that...

PaxMedica Inc. Featured in Syndicated Broadcast Highlighting FDA Type-B Meeting to Review PAX-101 Pivotal Trial Data

TARRYTOWN, NY / ACCESSWIRE / November 15, 2023 / PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, announced today a comprehensive...

PaxMedica, Inc. Announces Third Quarter 2023 Financial Results and Business Update

PaxMedica, Inc. (NASDAQ: PXMD) shares are trading higher on Tuesday. The stock has been volatile over the past month.
read more...

What's Going On With PaxMedica Stock Today?

LOS ANGELES, Nov. 09, 2023 (GLOBE NEWSWIRE) -- IBN, a leading communications organization focused on linking public companies to the investment community, has unveiled the latest episode of The...

PaxMedica's Chief Medical Officer Discusses FDA Meeting Highlights on The Bell2Bell Podcast

TARRYTOWN, NY / ACCESSWIRE / November 7, 2023 / PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, announced the publication of...

PaxMedica Announces Publication of Its Autism Spectrum Disorder Phase 2 Study Results in Peer-reviewed Journal

Acerus Pharmaceuticals (OTCMKTS:ASPCF  Get Free Report) and PaxMedica (NASDAQ:PXMD  Get Free Report) are both small-cap medical companies, but which is the better investment? We will...

Acerus Pharmaceuticals (OTCMKTS:ASPCF) vs. PaxMedica (NASDAQ:PXMD) Head to Head Survey

PaxMedica, Inc. is a clinical stage biopharmaceutical company. It engages in the business of developing drug candidates for the treatment of autism spectrum disorder, Fragile X syndrome tremor-ataxia, and Human African Trypanosomiasis. The company was founded by Michael L. Derby on April 5, 2018 and is headquartered in Tarrytown, NY.

Watchers	4,431
52-Wk Low	$0.7979
52-Wk High	$69.19

Volume (M)	900.00
52-Wk High	$69.19
52-Wk Low	$0.7979

Current Price	$0.92
Prev Close	$0.86
Open	$0.90
Dividend Yield	0.00%
50-Day Moving Average	$3.32
Beta	0.00
Avg. Volume	335,405.56
PE Ratio	-0.04

52-Week High	$69.19
52-Week Low	$0.7979
Market Capitalization	N/A
EPS	-$21.77
Price to Book	-1.84
Revenue Per Employee	N/A
Enterprise Value/EBITDA	-0.31

PXMD PaxMedica, Inc.

About

Feed

News

Earnings

Fundamentals